AddiQoL: Adrenal Insufficiency Quality of Life Scale
Adrenal Insufficiency Quality of Life Scale · Also known as: Addison Quality of Life, AI-QoL
AddiQoL is a disease-specific quality of life questionnaire developed to assess the burden of primary and secondary adrenal insufficiency, encompassing physical, emotional, and social domains relevant to patients on glucocorticoid and mineralocorticoid replacement therapy. Developed by Evers and Tiemensma in 2012, it is the first formally validated instrument specifically designed for adrenal insufficiency populations.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
AddiQoL is indicated for: (1) Baseline assessment at adrenal insufficiency diagnosis to establish quality of life burden and treatment targets; (2) Periodic monitoring (6-12 months) in established patients to track symptom evolution and medication optimization response; (3) Evaluation of quality of life impacts when considering therapy changes (glucocorticoid dose adjustments, mineralocorticoid modifications, novel agents); (4) Research studies investigating prevalence of quality of life burden and predictors in adrenal insufficiency populations; (5) Assessment of psychological morbidity (anxiety, depression) in this population with established high rates of mood disorder. Suitable for primary adrenal insufficiency (Addison disease) and secondary adrenal insufficiency (pituitary origin). Less data in tertiary adrenal insufficiency; applicability requires validation.
Strengths & limitations
- Disease-specific relevance: First formally validated instrument designed exclusively for adrenal insufficiency; captures concerns unique to this population (crisis risk anxiety, salt craving, medication burden) not assessed by generic quality of life measures.
- Comprehensive multidimensional approach: Covers physical symptoms, emotional impacts, social functioning, and uncertainty—reflecting the complex lived experience of patients managing a rare endocrine disorder.
- Psychometric rigor: Strong internal consistency (Cronbach alpha 0.85-0.92), test-retest reliability, and convergent validity with depression/anxiety screening tools.
- Clinical utility: Short administration time, simple scoring, and clear interpretation enable routine use in endocrinology practice and research settings.
- Limited responsiveness data: Fewer longitudinal studies compared to other endocrine quality of life instruments; minimal data on score changes expected with specific therapy modifications.
- Subscale structure complexity: Various versions (24-item, 27-item) with differing subscale configurations; standardization across versions would strengthen comparability.
- Rare disease context: Validation primarily in European adrenal insufficiency cohorts; limited data in non-European populations or in pediatric adrenal insufficiency.
- Psychological domain overlap: Emotional and Uncertainty subscales show moderate correlation; some items assess treatment burden rather than quality of life per se (medication frequency, side effects).
Frequently asked
What glucocorticoid dose corresponds to best AddiQoL scores?
No fixed cortisol dose predicts AddiQoL response; individual variation is substantial. Some patients achieve good quality of life at conventional hydrocortisone 20 mg/day, while others require higher doses or multiple daily doses. Extended-release formulations often produce modest score improvements; titration based on combined cortisol dynamics and AddiQoL subscale scores (fatigue, emotional stability) is recommended.
Can AddiQoL predict adrenal crisis risk?
No. AddiQoL measures quality of life impacts; it does not directly assess crisis risk. Patients with high anxiety subscale scores and low confidence scores may benefit from crisis training and contingency planning, but actual crisis risk depends on physiologic stress response and medication access, not quality of life perception.
Are there differences in AddiQoL between primary (Addison) and secondary adrenal insufficiency?
Minimal differences in mean total scores; however, subscale profiles differ: primary adrenal insufficiency shows higher salt craving and mineralocorticoid-related symptom burden; secondary adrenal insufficiency shows greater pituitary-related symptom overlap (from multiple hormone deficiencies). Separate interpretation by disease subtype recommended.
How is AddiQoL different from generic quality of life measures like SF-36?
SF-36 assesses general health-related quality of life; AddiQoL focuses on adrenal insufficiency-specific impacts (crisis anxiety, fatigue unique to hormone deficiency, medication burden). AddiQoL is more sensitive to disease-specific changes; SF-36 useful for comparing QoL burden to other chronic diseases (diabetes, thyroid disease). Combined administration provides complementary information.
Sources
- Evers, A. C., & Tiemensma, J. (2012). AddiQoL: A disease-specific quality of life scale for patients with primary adrenal insufficiency. J Clin Endocrinol Metab, 97(10), 3501-3508. link ↗
- Tiemensma, J., & Evers, A. C. (2014). Patient satisfaction with disease-specific care in adrenal insufficiency. Endocr Pract, 20(6), 551-558. link ↗
How to cite this page
ScholarGate. (2026, June 3). Adrenal Insufficiency Quality of Life Scale. ScholarGate. https://scholargate.app/en/endocrinology/adrenal-insufficiency-qol
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- AGHDAEndocrinology↔ compare
- Diabetes Symptom ChecklistEndocrinology↔ compare
- ThyPROEndocrinology↔ compare